[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-adult-male\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-adult-male":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,45,71,109,135,160,186,215,244,263,289,314,336,368,396],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100644240","phase-1-a-clinical-study-to-evaluate-the-safety-of-mf1-a-new-treatment-for-parkinsons-disease-related-disorders-mf1-study-100644240",false,"NCT07666022","A Clinical Study to Evaluate the Safety of MF1, a New Treatment for Parkinson's Disease-related Disorders (MF1 Study)","A Phase I Investigator-initiated First-in-human Study to Evaluate the Safety and Pharmacokinetics of MF1 in Healthy Adults and Patients With Parkinson's Disease (MF1-FIH)","Inclusion Criteria:\n\n(Parts A and B)\n\n* 1)Healthy Japanese male adults aged \\>=18 and \\\u003C45 years at the time of informed consent.\n* 2\\) Subjects with a body mass index (BMI) of \\>=18.5 and \\\u003C25.0 kg\u002Fm2 at screening.\n* 3\\) Subjects who have received sufficient explanation regarding the study from the principal investigator or subinvestigator, have understood the objectives of the study, voluntarily agreed to participate, and have provided written informed consent of their own free will.\n\n(Part C)\n\n* 1\\) Patients diagnosed with idiopathic Parkinson's disease according to the International Parkinson and Movement Disorder Society (MDS) Clinical Diagnostic Criteria (2015).\n* 2\\) Patients with Parkinson's disease classified as Stage 3 or below according to the modified Hoehn and Yahr staging scale.\n* 3\\) Patients who are either untreated or have been receiving one of the following treatments at a stable dosage regimen for at least 8 weeks prior to screening, with no planned changes during the study period: selegiline up to 5 mg twice daily, rasagiline up to 1 mg once daily, or immediate-release carbidopa\u002Flevodopa up to 25\u002F100 mg three times daily.\n* 4\\) Patients with an average Bristol Stool Scale score of \\\u003C=3 from the date of informed consent to eligibility assessment, or patients with fewer than two bowel movements per week.\n\nIf the period between informed consent and eligibility assessment is less than one week, information prior to informed consent will also be collected to assess bowel conditions for at least one week in total.\n\n* 5\\) Male or female patients aged \\>=40 and \\\u003C85 years at the time of informed consent.\n* 6\\) Patients with a BMI of \\>=18.5 and \\\u003C32.0 kg\u002Fm2 at screening.\n* 7\\) Female patients who are postmenopausal for at least one year at the time of informed consent, including menopause resulting from hysterectomy or oophorectomy.\n* 8\\) Patients who have received sufficient explanation regarding the study from the principal investigator or subinvestigator, have understood the objectives of the study, voluntarily agreed to participate, and have provided written informed consent of their own free will.\n\nExclusion Criteria:\n\n(Parts A and B)\n\n* 1\\) Subjects with clinically significant cardiovascular, neurological, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, immunological, endocrine, or psychiatric disorders, or any other abnormalities that may affect safety, increase seizure risk, lower seizure threshold, or confound study results.\n* 2\\) Subjects with current or past diseases or surgical histories involving the gastrointestinal tract, liver, kidneys, or other organs that may affect drug absorption, metabolism, or excretion.\n* 3\\) Subjects who used any medication, including over-the-counter drugs, within 7 days prior to the day before the first administration of the investigational product.\n* 4\\) Subjects with seizure disorders such as epilepsy, or a history thereof.\n* 5\\) Subjects with allergies or a history of allergies to drugs or foods.\n* 6\\) Subjects with allergic predisposition who are considered unsuitable for participation by the principal investigator or subinvestigator.\n* 7\\) Subjects with current or past alcohol or drug dependence.\n* 8\\) Subjects who donated \\>=400 mL of whole blood within 12 weeks, \\>=200 mL of whole blood within 4 weeks, or blood components within 2 weeks prior to investigational product administration.\n* 9\\) Subjects who tested positive at screening for HBs antigen, HCV antibody, HIV antigen\u002Fantibody, or syphilis serology (TP antibody test or RPR test).\n* 10\\) Subjects unwilling to use appropriate contraception from the time of informed consent until the final study visit.\n* 11\\) Subjects who answered \"Yes\" to Question 4 or 5 regarding suicidal ideation on the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening, or who had a history of suicidal behavior within 6 months prior to screening.\n* 12\\) Subjects who received investigational treatment in another clinical trial within 4 months prior to investigational product administration.\n* 13\\) Subjects judged unsuitable for study participation by the principal investigator or subinvestigator based on findings from screening or admission assessments, observations, or examinations.\n\n(Part C)\n\n* 1\\) Patients with drug-induced parkinsonism, metabolic neurogenetic disorders, encephalitis, Parkinson-plus syndromes, or other atypical parkinsonian syndromes.\n* 2\\) Patients with freezing of gait.\n* 3\\) Patients with a history of stereotactic brain surgery for Parkinson's disease (e.g., pallidotomy, deep brain stimulation, or fetal tissue transplantation).\n* 4\\) Patients with clinically significant cardiovascular, neurological, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, immunological, endocrine, or psychiatric disorders other than Parkinson's disease, or any other abnormalities that may affect safety, increase seizure risk, lower seizure threshold, or confound study results.\n* 5\\) Patients with current or past diseases or surgical histories involving the gastrointestinal tract, liver, kidneys, or other organs that may affect drug absorption, metabolism, or excretion.\n* 6\\) Patients with seizure disorders such as epilepsy, or a history thereof.\n* 7\\) Patients currently receiving antiplatelet agents or anticoagulants.\n* 8\\) Patients with allergies or a history of allergies to drugs or foods.\n* 9\\) Patients with allergic predisposition who are considered unsuitable for participation by the principal investigator or subinvestigator.\n* 10\\) Patients with current or past alcohol or drug dependence.\n* 11\\) Patients who donated \\>=400 mL of whole blood within 16 weeks, \\>=200 mL of whole blood within 4 weeks, or blood components within 2 weeks prior to investigational product administration.\n* 12\\) Patients who tested positive at screening for HBs antigen, HCV antibody, HIV antigen\u002Fantibody, or syphilis serology (TP antibody test or RPR test).\n* 13\\) Patients unwilling to use appropriate contraception from the time of informed consent until the final study visit.\n* 14\\) Patients who answered \"Yes\" to Question 4 or 5 regarding suicidal ideation on the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening, or who had a history of suicidal behavior within 6 months prior to screening.\n* 15\\) Patients who received investigational treatment in another clinical trial within 4 months prior to investigational product administration.\n* 16\\) Patients judged unsuitable for study participation by the principal investigator or subinvestigator based on findings from screening or admission assessments, observations, or examinations.",true,"ALL","18 Years","85 Years",{"count":21,"type":22},58,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a Phase I, investigator-initiated, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of MF1, a novel agent that is expected to inhibit α-synuclein related pathogenesis in α-synucleinopathies, primarily Parkinson's disease (PD). MF1 aims to address the unmet medical need in PD, which affects about 1% of individuals aged 60 years and older in Japan and is projected to reach 43 million patients worldwide by 2050.\n\nThe trial consists of three parts: Part A (single ascending dose) and Part B (multiple ascending dose) in healthy Japanese male adults, and Part C (multiple dose) in patients with idiopathic PD. Part A is a randomized, double-blind, placebo-controlled, single-center study assessing single oral doses , including a food-effect evaluation. Part B is a randomized, double-blind, placebo-controlled, single-center study with once-daily dosing for 7 days. Part C is an open-label, multicenter study in 4-8 PD patients (MDS 2015 criteria, Hoehn \\& Yahr stage ≤3) receiving once daily for 14 days, with or without stable background antiparkinsonian therapy.\n\nThe primary objective is to assess safety and tolerability; secondary objectives include characterization of plasma, urine, and cerebrospinal fluid pharmacokinetics and assessment of food effect. Exploratory pharmacodynamic endpoints include biomarkers such as α-synuclein, neurofilament light chain, UCHL-1, FABP3, GFAP, and other neurodegeneration markers.\n\nKey exclusion criteria include clinically significant systemic diseases, seizure history, serious infections (HBV, HCV, HIV, syphilis), recent suicidal ideation or attempts, and recent use of other investigational products.",[28,29],"Healthy Adult Male","PARKINSON DISEASE (Disorder)",[31],"FIH","RECRUITING","2026-06-18",{"date":35,"type":36},"2026-06-24","ACTUAL",{"date":38,"type":36},"2026-06-01",{"date":40,"type":22},"2028-10-31",{"name":42,"class":43},"University of Shizuoka","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100641929","apply-biphasic-ivm-for-poseidon-group-1-100641929","NCT07632300","Apply Biphasic IVM for POSEIDON Group 1","Efficacy and Safety of Biphasic IVM in Low Prognosis Patients Classified as Poseidon Group 1A","POSEIDON-Ia","Inclusion Criteria:\n\n* Women aged 18 - \\\u003C 35 years\n* At least one IVF cycle have been failed and classified as having a poor response to POSEIDON group Ia.\n* POSEIDON group Ia ( \\\u003C 35 age; AMH \\>= 1.2 ng\u002Fml and\u002For AFC \\>=5 antral follicles; have \\\u003C 4 oocytes was retrieved at previous IVF cycle)\n* Agree to apply biphasic-IVM treatment.\n* Agree to freeze all embryos and to transfer the frozen embryos afterward.\n* Agree to participate in the study.\n\nExclusion Criteria:\n\n* Egg-donation cycle\n* Uterine abnormalities: adenomyosis, large uterine fibroids (≥5 cm), bicornuate uterus, uterine adhesions.\n* Sperm surgical (PESA, TESE, mTESE)\n* PGT","FEMALE","35 Years",{"count":56,"type":22},25,[58],"NA","The goal of this clinical trial is to learn if biphasic In Vitro Maturation (IVM) works to help young women who produce very few oocytes after controlled ovarian stimulation. The study focuses on women under age 35 who have a good number of follicles in their ovaries but do not respond well to standard ovarian stimulation by Gonadotropin (known as POSEIDON Group 1a).\n\nThe main questions it aims to answer are:\n\nHow many mature oocytes can be obtain after biphasic -VM? Researchers will use biphasic-IVM system to see if it can bypass the problems these patients face with standard treatments, such as high costs and the risk of medical complications like Ovarian Hyperstimulation Syndrome (OHSS).\n\nParticipants will:\n\nHave their immature eggs collected from the ovaries without the need for high-dose hormone injections.\n\nHave their eggs matured in a specialized laboratory using a two-step process (biphasic IVM) to improve egg quality.\n\nFollow up with researchers to check the number of embryos created and the safety of the procedure.",[61,28],"Healthy Adult Females","2026-06-15",{"date":64,"type":36},"2026-06-17",{"date":66,"type":36},"2026-06-12",{"date":68,"type":22},"2027-03-30",{"name":70,"class":43},"Mỹ Đức Hospital",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":16,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":44},"100636093","effect-of-collavant-n2-in-healthy-male-adults-with-exercise-induced-joint-discomfort-100636093","NCT07561203","Effect of Collavant® n2 in Healthy Male Adults With Exercise-induced Joint Discomfort.","A Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Effect of Collavant® n2 on Joint Function and Performance in Healthy, Active Male Adults With Exercise-induced Joint Discomfort.","COLLMOTION","Inclusion Criteria:\n\n* Healthy physically active male adults (amateur runners) with exercise-induced joint discomfort, aged between 40 and 65 years\n* Activity level: Amateur runners who train regularly a minimum of 150 minutes per week, divided into 2 or more sessions per week during at least 3 months. Principally, subjects training for popular running events of 10 Kms.\n* Joint discomfort after activity: Self-reports target knee discomfort after training by a score of at least 20 mm VAS at screening. Discomfort persistent for at least 2w.\n* Be willing to refrain from starting any new dietary supplements during the entire study that have any underlying joint benefits (collagen, glucosamine, chondroitin, MSM, Hyaluronic Acid, Turmeric, Natural Eggshell Membrane, Omega-3 fatty acids, PEA, Boswellia,..). If any of these supplements (except collagen) or any other dietary supplement has been taken consistently for at least 6 months prior to enrollment, participants should maintain the same stable intake pattern throughout the 24 week study period.\n* Have individual devices to monitor training with GPS\n* Sign informed consent\n\nExclusion Criteria:\n\n* Diagnostic of knee osteoarthritis or any pathology or surgical intervention associated with the knee.\n* Hypersensitivity to any component of the supplement or the placebo\n* Chronic treatment with analgesic or anti-inflammatory (NSAIDs and corticosteroids families) drugs\n* Treatment with any type of collagen supplement\n* Treatment with probiotics or antibiotics\n* Inability to train for the next 24 weeks\n* Follow a vegan diet","MALE","40 Years","65 Years",{"count":83,"type":22},80,[58],"The present clinical study has been designed to evaluate the effect of Collavant® n2 at a daily dose of 40 mg on joint function and performance in healthy, amateur male runners with exercise-induced knee discomfort.",[28],[88,89,90,91,92,93,94,95,96,97,98],"Native type II collagen","Undenatured type II collagen","Collavant® n2","Joint discomfort","Knee discomfort","Joint function","Cartilage biomarkers","Healthy active adults","Amateur runners","Knee function","Exercise-induced joint discomfort","2026-05-11",{"date":101,"type":36},"2026-05-13",{"date":103,"type":36},"2026-05-06",{"date":105,"type":22},"2027-03",{"name":107,"class":108},"Bioiberica","INDUSTRY",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":80,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":44},"100636788","effect-of-gum-acacia-and-electrolytes-on-hydration-after-an-exercise-indued-dehydration-100636788","NCT07570238","Effect of Gum Acacia and Electrolytes on Hydration After an Exercise-indued Dehydration","A Single-blinded, Placebo-controlled, Three-way Crossover Pilot Study, to Assess the Rehydrating Effect of a Nutritional Preparation Containing Gum Acacia Combined With Sea Magnesium After Exercise-induced Dehydration","NEX\u002F008624","Inclusion Criteria:\n\n* BMI 18-25\n* Regular physical training on a recreational level\n* Resting pulse rate \\\u003C100; resting blood pressure \\\u003C140 mmHg\u002F\\\u003C100 mmHg\n\nExclusion Criteria:\n\n* Participant suffering from acute or recently occurred (in the past 2 weeks) sickness e.g. common cold or gastrointestinal problems\n* Injuries that would limit exercise performance\n* History or presence of cardiovascular, metabolic, endocrine musculoskeletal, autoimmune or renal condition\u002Fdisorder which per investigator's judgement could interfere with the results of the study or the safety of the participant",{"count":118,"type":22},24,[58],"This clinical study is a single-blind, placebo-controlled, three-way cross-over trial evaluating the rehydration efficacy of two nutritional beverages compared to water, after one administration. The investigational products are gum acacia alone, and combined with sea electrolytes as magnesium. Participants, physically active men undergo exercise-induced dehydration followed by controlled rehydration procedure with each product in randomized sequence. The study includes standardized preconditions (diet, hydration, activity control), exercise and rehydration protocols.\n\nGam acacia has the benefit of few preclinic studies in murin models showing significant improvements on electrolytes and water absorption, but its effect on hydration in human has never been evaluated.\n\nThe combination with sea electrolytes has been developed to optimise and reduce the total concentration of electrolytes into the beverage compared to standard formulations proposed for rehydration in sport application.",[28],[123,124,125],"hydration","gum acacia","magnesium","NOT_YET_RECRUITING",{"date":128,"type":36},"2026-05-14",{"date":130,"type":22},"2026-05",{"date":132,"type":22},"2026-08",{"name":134,"class":108},"Nexira",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100621867","phase-1-single-ascending-dose-study-of-hec-151-injection-100621867","NCT07376200","Single-ascending Dose Study of HEC-151 Injection","An I-phase Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic\u002FPharmacodynamic Characteristics of a Single Dose of HEC-151 Injection in Healthy Chinese Participants in a Single-center, Randomized, Placebo (Single-blind) and Positive Control (Open-label) Study","Inclusion Criteria:\n\n1. Voluntarily participate in the trial and sign the informed consent form, understanding and abiding by the research procedures;\n2. When signing the informed consent form, men aged 18-45 years old (including the boundary value) are eligible;\n3. During the screening process, male subjects with a body weight of ≥ 50 kg and a body mass index (BMI) of ≥ 19.0 and ≤ 24.0 kg\u002Fm2 are included;\n4. Normal glucose tolerance \\[3.9 mmol\u002FL \\\u003C fasting blood glucose (FPG) \\\u003C 6.1 mmol\u002FL, and 2-hour post-glucose tolerance test (OGTT) blood glucose after sugar intake \\\u003C 7.8 mmol\u002FL\\];\n5. Normal results of insulin release test (IRT), or abnormal results but judged by the researcher to have no clinical significance;\n6. Glycated hemoglobin (HbA1c) \\\u003C 5.7%;\n7. During the study period, there are no plans for reproduction, sperm collection, or sperm donation, and are willing to take effective contraceptive measures throughout the study period until 3 months after the administration of the investigational drug.\n\nExclusion Criteria:\n\n1. Participants with abnormal medical histories or surgical histories judged clinically significant by the researchers, or currently suffering from any diseases in the endocrine system, blood system, cardiovascular system, respiratory system, digestive system, urinary system, immune system, nervous system, etc. that are judged clinically significant by the researchers, or any other diseases or physiological conditions that can significantly affect the absorption, distribution, metabolism or excretion of the drugs;\n2. Participants who have a known severe allergic history or are allergic to the test drugs and any of their components;\n3. Participants who had severe trauma or undergone surgery within 90 days before the screening, or plan to undergo major surgery during the study;\n4. Participants who have a history of hypoglycemia or hyperglycemia within 90 days before the screening, or have a family history of diabetes (first-degree direct relatives);\n5. Participants who have donated blood or suffered significant blood loss (≥ 400 mL) within 90 days before the screening, or plan to donate blood during the study;\n6. Participants who have acute diseases or concurrent medication use from the signing of the informed consent form to the first administration of the drug;\n7. Participants whose vital signs, physical examination, laboratory tests, electrocardiogram, chest X-ray examination, etc. results are abnormal and judged by the researchers to have clinical significance;\n8. Participants whose test results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV), combined human immunodeficiency virus antigen antibody (HIV), or syphilis spirochete antibody (TP) are positive;\n9. Participants who have a history of drug abuse or drug use, or whose urine drug screening is positive before the screening;\n10. Participants who have used any prescription drugs, Chinese herbal medicines, over-the-counter drugs, health supplements (except for regular supplementary vitamins and calcium) within 30 days before the screening;\n11. Participants who have participated in any clinical research of drugs or devices (defined as receiving the test drugs or devices) within 90 days before the screening;\n12. Participants who have received any vaccine within 30 days before the screening, or plan to receive any type of vaccine during the study;\n13. Participants who smoke more than 5 cigarettes per day within 90 days before the screening, or cannot comply with the smoking prohibition rule during the study;\n14. Participants who frequently drink alcohol, that is, consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine), or have a positive alcohol breath test; or who cannot comply with the alcohol prohibition rule during the study;\n15. Participants who consume excessive tea, coffee and\u002For caffeine-rich beverages (more than 8 cups, 1 cup ≈ 250 mL) or food (such as chocolate) every day within 90 days before the screening, or during the study;\n16. Participants who have used special diets (including dragon fruit, mango, pomelo, etc.) and\u002For xanthine diet (salmon, sardines, liver, kidney, etc.) or have other factors affecting drug absorption, distribution, metabolism, and excretion before the signing of the informed consent form to the use of the test drugs, or who cannot comply with the prohibition of eating during the study;\n17. Participants who have had significant changes in diet or exercise habits within 90 days before the screening, or have engaged in intense exercise before the signing of the informed consent form to the use of the test drugs, or cannot stop during the study;\n18. Participants who have difficulty in venous blood collection, or cannot tolerate venipuncture, or have a history of fainting or hematemesis;\n19. Participants who, in the researcher's opinion, have other factors that are not suitable for participating in this study.","45 Years",{"count":144,"type":22},81,[25],"Evaluate the safety, tolerability, PK\u002FPD and immunogenicity characteristics of a single subcutaneous HEC-151 Injection solution in healthy participants",[28],[149],"HEC-151 Injection","2026-04-23",{"date":152,"type":36},"2026-04-29",{"date":154,"type":36},"2026-02-24",{"date":156,"type":22},"2026-09-27",{"name":158,"class":108},"Sunshine Lake Pharma Co., Ltd.",2,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":81,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":44},"100631447","effect-of-early-time-restricted-eating-on-appetite-appetite-regulatory-hormones-and-energy-intake-100631447","NCT07500792","Effect of Early Time-Restricted Eating on Appetite, Appetite-Regulatory Hormones and Energy Intake","Effect of One Day Early Time-Restricted Eating (eTRE) on Appetite, Appetite-Regulatory Hormones and Energy Intake in Healthy Men Without Obesity","Inclusion Criteria:\n\n* Males aged 18 years or older.\n* BMI between 18.5 and 24.9 kg\u002Fm²\n* Have stable body mass for at least three months (within ±2 kg).\n\nExclusion Criteria:\n\n* Females\n* People who are younger than 18 or older than 65 years old.\n* Following a special diet (e.g. weight loss, vegetarian or vegan, etc.).\n* Have food allergies related to the study.\n* Smoking.\n* Taking any medications.\n* Suffering from metabolic health issues, e.g., history of diabetes, cardiovascular disease, or eating disorders.",{"count":168,"type":22},12,[58],"This randomised crossover study's primary aim is to investigate the effect of short-term fasting (eTRE) on subjective appetite and appetite-regulatory hormones (i.e., leptin, adiponectin, total glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), total peptide YY (PYY), acylated ghrelin and Insulin). In addition, to examine if the one-day early time-restricted eating influences energy expenditure and ad libitum energy intake in the periods following the standard meal test. The researchers will compare normal eating with early Time-Restricted Eating (eTRE) in healthy men.",[28],[173,174,175,176],"appetite-regulatory hormones","subjective appetite","early time-restricted eating","energy intake","2026-04-13",{"date":179,"type":36},"2026-04-16",{"date":181,"type":22},"2026-05-01",{"date":183,"type":22},"2027-11-30",{"name":185,"class":43},"University of Glasgow",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":16,"sex":17,"minAge":80,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":196,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":44},"100632463","examining-olive-oil-extract-on-knee-comfort-and-function-100632463","NCT07514013","Examining Olive Oil Extract on Knee Comfort and Function","A 6-Week, Randomized, Double-Blind, Placebo-Controlled Virtual Study Evaluating an Olive Oil Extract on Knee Comfort and Function","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible for participation:\n\n* Adults aged 40 to 75 years\n* Self-reported knee discomfort for at least 3 months\n* Willing and able to take one study capsule daily for the duration of the study\n* Willing and able to complete digital questionnaires, functional movement tasks, and other study activities using the Alethios platform\n* Willing and able to wear a compatible activity-tracking device throughout the study\n* Willing and able to collect saliva samples at home using a provided kit, if applicable\n* Able to read and understand English\n* Willing to provide informed consent electronically\n\nExclusion Criteria:\n\nParticipants will be excluded if any of the following apply:\n\n* Diagnosis of inflammatory joint disease (e.g., rheumatoid arthritis) or other systemic inflammatory conditions affecting the knee\n* Any current or prior diagnosis from a licensed medical provider of knee disease\n* Knee surgery or significant knee injury within the past 6 months\n* Planned knee surgery during the study period\n* Known allergy or sensitivity to olive-derived products or any component of the study product\n* Current use of investigational drugs or participation in another research study during the study period\n* Any medical condition or circumstance that, in the opinion of the investigator, would make participation unsafe or interfere with study participation or data quality","75 Years",{"count":195,"type":22},168,[58],"The goal of this study is to learn if an olive oil extract works to improve knee pain and discomfort in adults. The main questions it aims to answer are: 1) Does the olive oil extract improve the perceptions of knee pain and discomfort, and 2) Does the olive oil extract improve knee function in adults?\n\nThe main procedures in the study include:\n\n* Screening and informed consent\n* Take one assigned study capsule (supplement or placebo) daily with food for 6 weeks\n* Complete digital questionnaires about your knee pain, stiffness, and function at scheduled times\n* Complete a Day 1 acute assessment and two simple functional movement tests at home as described below\n* If possible, connect a compatible wearable device to allow collection of sleep and physical activity data as detailed below.\n* Collect saliva samples at home using a provided kit at designated timepoints\n* Record any pain medications taken during the study or any side effects",[28,61,199],"Joint Discomfort",[201,202,203,204,205],"olive oil extract","randomized","double-blind","placebo","joint discomfort","2026-04-10",{"date":208,"type":36},"2026-04-15",{"date":210,"type":22},"2026-04",{"date":212,"type":22},"2026-11-01",{"name":214,"class":108},"Applied Food Sciences Inc.",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":232,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":44},"100610787","phase-1-a-study-to-evaluate-the-safety-of-increasing-doses-of-df5112-in-healthy-adults-100610787","NCT07232121","A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy Adults","A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacodynamics of DF5112 in Healthy Adult Participants","DF5112","Key Inclusion Criteria:\n\n* Male or female participants aged 18 to 55 years (inclusive) at the time of informed consent.\n* Body mass index (BMI) between ≥ 18.0 and ≤ 32.0 kg\u002Fm2 and body weight ≥ 45 kg.\n* At the discretion of the Principal Investigator (PI) or designee, in good general health, with no significant medical history, and have no clinically significant abnormalities on physical examination at Screening and\u002For before the first administration of IP.\n* Clinical laboratory values within normal range as specified by the testing laboratory, unless deemed not clinically significant by the PI or designee.\n\nKey Exclusion Criteria:\n\n* History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders that, in the opinion of the PI or designee, are capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.\n* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or metastases (except for squamous and basal cell carcinoma of the skin or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).\n* History of or evidence of recurrent or chronic bacterial or fungal infections including those of the skin, vagina, oral cavity, etc., or systemic fungal infection.\n* History of unexplained, recurrent infection, or infection requiring treatment with systemic antibiotics within 90 days prior to dosing on Day 1.\n* Active oral infection.\n* Acute illness (e.g. common cold) within 2 weeks prior to Screening, or seasonal influenza or COVID within 4 weeks prior to Screening.\n* History of latent or active tuberculosis that has not been adequately treated, at the discretion of the PI or designee.\n* Positive or inconclusive hepatitis B or hepatitis C based antibody tests at Screening.\n* Positive human immunodeficiency virus (HIV) antibody test at Screening.\n* History of severe allergy, hypersensitivity reaction, or anaphylaxis to drugs or human proteins or components of the study drug formulation used in this study.\n* Any vaccination within 1 month of Day 1 and planned within 1 month post Day 1. Any live or attenuated vaccine within 1 month prior to Day 1 and planned within 3 months post Day 1.","55 Years",{"count":225,"type":22},48,[25],"This is a double-blind, randomized, placebo-controlled, single ascending dose (SAD) study to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of DF5112 in healthy adult participants. A total of 48 participants are planned to be randomized into 6 cohorts. Additional cohorts at intermediate dose levels may be evaluated. Each cohort will include 8 healthy participants randomized to receive DF5112 or placebo through intravenous (IV) or subcutaneous (SC) administration. Following dose administration participants will be confined at the clinical research unit for observation for approximately 1 week and then will return for subsequent pre-identified follow up visits through Day 29.",[229,61,28,230,231],"Healthy Participants","Healthy","Volunteer",[233,234],"Healthy Volunteer","Healthy Participant","2026-03-26",{"date":237,"type":36},"2026-04-01",{"date":239,"type":36},"2026-01-12",{"date":241,"type":22},"2026-12",{"name":243,"class":108},"Dragonfly Therapeutics",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":142,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":261,"locationsCount":44},"100630224","phase-1-a-study-to-evaluate-the-safety-pk-and-immunogenicity-of-recombinant-human-hyaluronidase-in-healthy-subjects-100630224","NCT07484893","A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects","A Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Chinese Adult Male Subjects","Inclusion Criteria:\n\n* Healthy male subjects, aged ≥ 18 and ≤ 45 years.\n* Body Mass Index (BMI) ≥ 18.0 and ≤ 28.0 kg\u002Fm².\n* Intact skin at the injection site, with no damage, tattoos, or other markings.\n* No significant medical history, or a history of abnormalities that, in the investigator's judgment, will not impact the study.\n* Physical examination, vital signs, electrocardiogram (ECG), chest X-ray, and clinical laboratory tests are normal or abnormal without clinical significance (NCS).\n* Subjects must agree to use highly effective contraception with their spouse or partner from the time of signing the Informed Consent Form (ICF) until 3 months after the last dose, or the subject is not capable of reproduction. Subjects must also refrain from sperm donation during the study and for 3 months following the last dose of the investigational product.\n* Voluntarily signed the Informed Consent Form (ICF) prior to any study procedures, with a full understanding of the study content, procedures, and potential adverse events (AEs); and the ability to comply with the protocol requirements to complete the study.\n\nExclusion Criteria:\n\n* History of drug abuse or or substance use, or a positive drug screen; history of long-term heavy alcohol consumption (defined as consuming more than 14 units of alcohol per week within 3 months prior to screening \\[1 unit = 360 mL of beer, or 45 mL of spirits with 40% alcohol content, or 150 mL of wine\\]) or a positive blood alcohol test; history of long-term heavy alcohol use or positive blood alcohol test; history of long-term heavy smoking (defined as an average of more than 5 cigarettes per day within 3 months prior to screening, or inability to abstain from smoking during the ).\n* Cardiac disorders, including but not limited to clinically significant ECG abnormalities during the screening period, QTcF \\> 450ms, or a history of clinically significant ECG abnormalities.\n* History of any clinically severe hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or oncological diseases, or allergic diseases.\n* History of upper respiratory tract infection or other acute infections within 7 days prior to the first dose, or systemic use of antibiotics within 7 days.\n* Known allergy to recombinant human hyaluronidase for injection or its formulation components; history of severe allergic reactions to any medication (e.g., angioedema); special dietary requirements or inability to comply with the standardized diet provided by the clinical site.\n* Use of any prescription drugs, over-the-counter (OTC) medications, or herbal medicines within 4 weeks prior to screening (especially salicylates, cortisone, adrenocorticotropic hormone, estrogens, or antihistamines, except for routine vitamin supplements), or within 5 half-lives of the medication (whichever is longer).\n* Vaccination within 1 month prior to administration.\n* History of blood donation or blood loss ≥ 400 mL within 3 months prior to the use of the investigational product.\n* Participation in any other clinical study and use of investigational\u002Fcontrol products within 3 months prior to the investigational product administration.\n* Positive for HBsAg, anti-HCV, anti-HIV, or the syphilis spirochete test.\n* Sensory-motor disorders or autonomic movement disorders.\n* Any condition which, in the investigator's judgment, would make the subject unable to comply with the protocol requirements, instructions, or study restrictions, such as an uncooperative attitude, inability to return for follow-up visits, or inability to complete the study.",{"count":118,"type":22},[25],"The study is being conducted to evaluate the safety, pharmacokinetics, and immunogenicity of recombinant human hyaluronidase in healthy Chinese adult male subjects.",[28],"2026-03-16",{"date":257,"type":36},"2026-03-20",{"date":128,"type":22},{"date":260,"type":22},"2026-10-24",{"name":262,"class":108},"Shanghai Henlius Biotech",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":142,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":276,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":287,"locationsCount":4},"100629616","effects-of-dual-source-carbohydrate-intake-and-liver-glycogen-repletion-after-overnight-fasting-100629616","NCT07476989","Effects of Dual-Source Carbohydrate Intake and Liver Glycogen Repletion After Overnight Fasting.","The Effects of a Dual-Source High-Carbohydrate Breakfast on Hepatic Glycogen Storage Following an Overnight Fast.","Inclusion Criteria:\n\n* A male (at birth) aged between 18 and 45.\n* Regularly training for a specific sport (must include cycling) at least 3 times per week (with the purpose of competing).\n* VO2 peak \\>50 (ml.kg.min)\n* A current non-smoker\u002Fvaper (must not have smoked or vaped within the last 6 months)\n* Do not have any medical conditions or are taking any medications or supplements which can affect the study's outcome measures.\n* Free from any metallic implants, including permanent jewellery (that can't be removed)\n* No known intolerances or allergies to any component of the nutritional supplement\n\nExclusion Criteria:\n\n* Are not a male (at birth) aged between 18 and 45.\n* Do not regularly train for a specific sport (must include cycling) at least 3 times per week (with the purpose of competing).\n* Does not have a VO2 max\u002Fpeak \\>50 (ml.kg.min)\n* A current smoker\u002Fvaper (must not have smoked or vaped within the last 6 months)\n* Have any medical conditions or are taking any medications or supplements which can affect the study's outcome measures\n* Have any metallic implants, including permanent jewellery (that can't be removed)\n* Known intolerances or allergies to any component of the nutritional supplement.",{"count":168,"type":22},[58],"This study is looking at whether eating a breakfast which has two different sources of carbohydrates, glucose and fructose (found in foods like honey and fruits), can increase how much glycogen can be stored in the liver. Glucose is a type of sugar that the body uses to provide energy during exercise. When it is not circulating in the blood, it is stored in the muscles and liver. The stored version of glucose is often referred to as glycogen. When the body needs energy, for example, it will break down glycogen into glucose so that it can be used as fuel.\n\nMuscle and liver glycogen stores are vital in providing energy during prolonged exercise, and strenuous activity can rapidly deplete these stores, leading to increased fatigue and a decline in performance. Liver glycogen, however, is particularly important because it controls blood glucose levels. This is important because the brain and other organs are constantly relying on the supply of glucose to function properly.\n\nWhen sleeping, the body goes through a natural period of fasting. During this period, the liver gradually breaks down its glycogen stores to release glucose into the bloodstream. Because of this, following sleep, liver glycogen stores are automatically low (which is why having breakfast is important). There is research to suggest that eating a high-carbohydrate breakfast can prevent further declines in liver glycogen; however, it is not known if eating different types of carbohydrates within the breakfast (glucose and fructose together) will affect the liver's ability to store glycogen. This research will aid in understanding optimal ways to increase liver glycogen stores before performing exercise, which may influence exercise performance.\n\nTherefore, the main aim of this study is:\n\n1\\. Investigate whether a high fructose breakfast will increase liver glycogen storage\n\nTo achieve this, participants will be recruited to complete a randomised crossover study where they will undertake three different conditions. All laboratory trials will take place at the Manchester Metropolitan University Institute of Sport.\n\n1. No breakfast (Control)\n2. 3 g\u002Fkg of body mass of carbohydrate (of which contains 0% fructose)\n3. 3 g\u002Fkg of body mass of carbohydrate (of which contains50% fructose)\n\nLiver glycogen stores will be measured using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). The investigators will measure liver glycogen content, liver volume, and stomach volume. Blood samples will also be taken to measure different metabolic hormone responses.",[274,275,28],"Carbohydrate Metabolism","Hepatic Glycogen Storage",[277,278,279,280],"Glucose","Fructose","Liver glycogen storage","Magnetic resonance spectroscopy","2026-03-12",{"date":283,"type":36},"2026-03-17",{"date":285,"type":22},"2026-03",{"date":241,"type":22},{"name":288,"class":43},"Manchester Metropolitan University",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":23,"phases":299,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":44},"100625692","oxytocins-effects-on-emotional-processing-and-its-acting-routes-100625692","NCT07425938","Oxytocin's Effects on Emotional Processing and Its Acting Routes","The Modulatory Effects of Oxytocin on Emotional Processing and Its Acting Routes","Inclusion Criteria:\n\n* Healthy subjects without past or current psychiatric or neurological disorders\n\nExclusion Criteria:\n\n* History of head injury.\n* Medical or psychiatric illness.\n* Subjects take a certain drug for a long period of time.\n* Subjects have metal implants in their bodies.","30 Years",{"count":298,"type":22},120,[58],"The main goal of this study is to investigate the modulatory effects of intranasally administrated oxytocin on the processing of emotional stimuli and its acting routes.",[28],[303,304,305],"oxytocin","negative emotion","vasoconstrictor","2026-02-20",{"date":308,"type":36},"2026-02-23",{"date":310,"type":36},"2026-01-24",{"date":208,"type":22},{"name":313,"class":43},"University of Electronic Science and Technology of China",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":16,"sex":79,"minAge":321,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":334,"locationsCount":44},"100618625","effect-of-vitamin-d-and-branched-chain-amino-acids-on-physical-performance-and-biomarkers-of-muscle-fatigue-in-runners-100618625","NCT07334054","Effect of Vitamin D and Branched-chain Amino Acids on Physical Performance and Biomarkers of Muscle Fatigue in Runners","Effect of Vitamin D and Branched-chain Amino Acids on Physical Performance and Biomarkers of Muscle Fatigue in Runners: an 8-week Randomized, Double-blind","Inclusion Criteria:\n\n* Adults aged 25 to 44\n* Men\n* Agree to participate in the study\n* Sign a consent form\n* Experience in long-distance running\n\nExclusion Criteria:\n\n* Have a previous diagnosis of liver disease, asthma, hypertension, diabetes, cancer, anemia\n* Have a previous diagnosis of a neurological disorder (Alzheimer's disease, Parkinson's disease, epilepsy)\n* Have a musculoskeletal disability\n* Be on medication or supplementation\n* Hypervitaminosis D (\\>100 ng\u002FmL)\n* Be on a structured training program\n* Use anabolic steroids","25 Years","44 Years",{"count":324,"type":22},64,[58],"Muscle fatigue caused by physical training is understood as a condition related to the inability to maintain action potential, derived from the alteration in skeletal muscle homeostasis. In long-distance recreational runners, prolonged physical work is performed while maintaining the level of intensity, where a level of fatigue intervenes, which overlaps and generates tiredness to execute the movement continuously. In the last 10 years, sports supplementation has been explored as an aid to increase physical performance, improve muscle recovery and prevent sports injuries.",[28,328],"Runners","2026-01-05",{"date":239,"type":36},{"date":332,"type":22},"2026-01-01",{"date":38,"type":22},{"name":335,"class":43},"Pedro Julian Flores Moreno",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":54,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":347,"conditions":348,"keywords":351,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":44},"100615646","early-phase-1-effect-of-antifungals-on-the-intestinal-microbiome---a-randomized-controlled-proof-of-concept-trial-100615646","NCT07295314","Effect of Antifungals on the Intestinal Microbiome - a Randomized, Controlled, Proof-of-concept Trial","FAME","Inclusion Criteria:\n\n* Male, 18-35 years of age at the time of signing informed consent\n* Healthy, as determined by medical history and physical examination; minor clinical abnormalities allowed if not introducing additional risk or interfering with study procedures\n* Capable of giving written informed consent and able to comply with study requirements\n* Normal defecation pattern (≤3 times\u002Fday and ≥3 times\u002Fweek)\n\nExclusion Criteria:\n\n* Major illness in the past 3 months, or significant chronic medical illness deemed unfavorable for enrollment\n* Past or current gastrointestinal disease that may influence the gut microbiota (including inflammatory bowel disease or medication-treated irritable bowel syndrome)\n* History of immunodeficiency\n* History of malignancy\n* Alcohol intake \\>3 units\u002Fday on average\n* Known allergy to antifungal drugs\n* Use of antibiotics (except topical) within the past 3 months\n* Use of antifungals (except topical) within the past 3 months\n* Planned prolonged travel (\\>4 weeks) to tropical countries during the study period\n* Receipt of an investigational product within 3 months prior to study day 0\n* Use of prescription or non-prescription drugs, herbal or dietary supplements within 3 months (unless deemed safe by investigator)\n* Difficulty with blood donation or poor venous access in either arm\n* Donation of \\>500 mL of blood in the past 3 months\n* Any other condition or circumstance that, in the investigator's opinion, could be harmful to the subject or compromise data interpretation",{"count":344,"type":22},50,[346],"EARLY_PHASE1","The goal of this clinical trial is to learn how the antifungal drug fluconazole affects the gut microbiome and immune system in healthy volunteers.\n\nThe main questions it aims to answer are:\n\n* Does fluconazole change the gut bacteriome and mycobiome composition after 14 days of treatment?\n* How long do these changes last (4 weeks and 6 months after treatment)?\n* Does fluconazole affect the body's immune responses, such as blood cell activity and antifungal antibodies?\n\nResearchers will compare two groups: participants who take fluconazole for 14 days and participants who receive no intervention.\n\nParticipants will:\n\n* Either take one fluconazole tablet (200 mg) daily for 14 days, or receive no treatment\n* Provide stool samples and blood samples at several timepoints\n* Return for follow-up visits up to 6 months after treatment\n\nThis study is conducted at Amsterdam UMC, location AMC, with a planned enrollment of 50 healthy male volunteers aged 18-35 years.",[349,28,350],"Gut Microbiome","Antifungal Therapy",[352,353,354,355,356,357,358],"Fluconazole","Antifungal Drugs","Mycobiome","Bacteriome","Microbiota Diversity","Innate Immune Response","Healthy Volunteers","2025-12-08",{"date":361,"type":36},"2025-12-19",{"date":363,"type":22},"2026-01",{"date":365,"type":22},"2027-12",{"name":367,"class":43},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":142,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":377,"briefSummary":378,"conditions":379,"keywords":380,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":395},"100606910","phase-1-a-study-of-pharmacokinetics-safety-and-immunogenicity-of-bcd-057-100-mgml-bcd-057-50-mgml-and-humira-100-mgml-in-healthy-subjects-100606910","NCT07181694","A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg\u002FmL, BCD-057 50 mg\u002FmL, and Humira 100 mg\u002FmL in Healthy Subjects","A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of Single Subcutaneous Doses of BCD 057 100 mg\u002FmL, BCD-057 50 mg\u002FmL, and Humira 100 mg\u002FmL in Healthy Subjects","Inclusion Criteria:\n\n1. Signing the Informed Consent Form of the study.\n2. Men aged 18-45 years inclusive at the time of signing the Informed Consent Form.\n3. Body mass index (BMI) in the range of 18.5-30.0 kg\u002Fm2.\n4. The confirmed \"healthy\" status based on the conventional clinical and laboratory assessments and investigations obtained as screening.\n5. Hemodynamic parameters within the normal range: systolic blood pressure (SBP) in the range of 100-130 mmHg, diastolic (DBP) in the range of 60-90 mmHg, wrist pulse rate 60-90 bpm, obtained at screening.\n6. ECG data normal for the age (no ischemia, arrhythmia, conduction disorders).\n7. No chronic infections (HIV, hepatitis B or C) and no history of chronic inflammatory diseases.\n8. No signs of active or latent tuberculosis according to screening X-ray and tuberculosis test results.\n9. No acute infections within 4 weeks prior to the date of randomization.\n10. The ability of the subject to follow the Protocol procedures, according to the Investigator.\n11. No history of alcoholism or drug addiction and negative test results for alcohol, psychotropic and narcotic substances, psychoactive drugs at screening and before the IP administration.\n12. Willingness of subjects to use condoms during any sexual contact by penetration with persons of any sex, including pregnant women, starting from the signing of the Informed Consent Form, during the study and for 5 months after the IP administration. This requirement does not apply to subjects who have undergone surgical sterilization (bilateral orchiectomy).\n13. Willingness to refuse to donate sperm and conceive a child starting from the signing of the Informed Consent Form, during the study and for 5 months after the IP administration.\n14. Willingness not to drink alcohol within 24 hours before and after the IP administration, within 24 hours before each scheduled visit.\n15. Willingness to refrain from smoking within 2 hours before the IP administration and then 2 hours before each measurement of blood pressure (BP), wrist pulse rate, respiratory rate, blood sampling, ECG.\n16. Willingness to refrain from vaccination with live attenuated vaccines (e.g., intranasal influenza, measles, mumps, rubella, polio, BCG, yellow fever, chickenpox, and typhoid TY21a vaccines) throughout the study.\n17. Willingness to refrain from taking any medications, including over-the-counter drugs, vitamins and food supplements, with the exception of drugs prescribed by the Investigator for the treatment of AEs, throughout the study.\n\nExclusion Criteria:\n\n1. Mental illness or other conditions that may, in the Investigator's opinion, affect the subject's ability to comply with the Study Protocol.\n2. Any significant, in the Investigator's opinion, surgical procedures performed less than 30 days before the screening examination and potentially affecting clinical study results.\n3. A history of allergic reactions (anaphylactic shock or multiple drug allergy according to the Investigator's assessment).\n4. Known allergy or intolerance to monoclonal antibody products (murine, chimeric, humanized, fully human) or any other components of the IP.\n5. Impossibility of installing a venous catheter for collecting blood samples (e.g., due to skin disorders at the venipuncture sites).\n6. Administration and use of the following drugs:\n\n   1. Past use of adalimumab or any other drugs that inhibit tumor necrosis factor alpha.\n   2. Regular oral or parenteral administration of any medicinal products, including over-the-counter drugs, vitamins, and dietary supplements, less than 14 days prior to the estimated date of randomization.\n   3. Taking medications, including over-the-counter drugs, which have a pronounced effect on hemodynamics and liver function (barbiturates, omeprazole, cimetidine, etc.), less than 30 days before the estimated date of randomization.\n   4. Using drugs that affect the immune status (cytokines and their inducers, glucocorticoids, etc.) less than 30 days before the estimated date of randomization.\n   5. Systemic use of antibacterial, antifungal, antiviral or antiprotozoal drugs less than 30 days before the estimated date of randomization.\n   6. Vaccination with live attenuated vaccines within 4 weeks before the estimated date of randomization.\n7. Positive results of screening tests for HIV, hepatitis B and C viruses.\n8. Results of conventional laboratory tests or investigations out of the reference ranges accepted at the study sites.\n9. Chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, kidneys, blood.\n10. Acute infectious diseases less than 4 weeks before the estimated date of randomization, as well as chronic and other diseases that, in the Investigator's opinion, may affect the pharmacokinetics, safety, and immunogenicity of the IP.\n11. Smoking more than 10 cigarettes a day.\n12. Consumption of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to ½ L of beer, 200 mL of wine or 50 mL of spirits) or a history of alcoholism, drug addiction, or drug abuse.of blood or plasma within 60 calendar days prior to the expected date of randomization.\n13. Donation of ≥450 mL of blood or plasma within 60 calendar days prior to the expected date of randomization.\n14. Participation in any clinical studies in less than 90 calendar days before the date of randomization, if the subject received a medicinal product during the clinical study.\n15. Previous participation in the same study if the subject was randomized and received the IP during the study.",{"count":376,"type":22},444,[25],"The aim of this study is to establish comparability of pharmacokinetic parameters and similarity of the safety and immunogenicity profiles of single subcutaneous doses of BCD 057 100 mg\u002FmL and BCD-057 50 mg\u002FmL, as well as BCD-057 100 mg\u002FmL and Humira 100 mg\u002FmL, in healthy subjects. The study is conducted in a population of healthy male subjects aged 18-45 years inclusive at the time of signing the ICF, with a body mass index in the range of 18.5 to 30.0 kg\u002Fm2.",[28],[381,382,383,384,385],"Tumor Necrosis Factor Inhibitors","Anti-Inflammatory Agents","Adalimumab","Monoclonal Antibody","Pharmacokinetics","2025-09-30",{"date":388,"type":36},"2025-10-03",{"date":390,"type":36},"2025-03-12",{"date":392,"type":22},"2025-11",{"name":394,"class":108},"Biocad",4,{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":16,"sex":79,"minAge":18,"maxAge":54,"enrollmentInfo":404,"targetDuration":4,"studyType":23,"phases":406,"briefSummary":407,"conditions":408,"keywords":409,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":44},"100603724","early-phase-1-the-effect-of-oral-oxytocin-and-atosiban-on-top-down-attention--otatosiban--100603724","NCT07140237","The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )","The Influence and Regulatory Role of Exogenous and Endogenous Oxytocin on Top-down Attention in Humans","OTAtosiban","Inclusion Criteria:\n\n* Healthy male subjects without past or current psychiatric or neurological disorders\n\nExclusion Criteria:\n\n* History of or current neurological\u002Fpsychiatric disorders;\n* Use of psychotropic medications (including nicotine)\n* Visual impairments",{"count":405,"type":22},250,[346],"The main aim of the present study is to investigate whether orally (lingual spray) administered oxytocin influences human top-down attention via oxytocin receptors and whether its effects are dose- and task-dependent.",[28],[410,411,412,413,414,415],"Oxytocin; Atosiban; Eye-tracking; Autistic trait","Oxytocin","Atosiban","Eye-tracking","Autistic trait","attention","2025-09-05",{"date":418,"type":36},"2025-09-08",{"date":420,"type":22},"2025-09",{"date":422,"type":22},"2025-12-30",{"name":313,"class":43}]